Pleural effects of indium phosphide in B6C3F1 mice: Nonfibrous particulate induced pleural fibrosis

Experimental Lung Research

Volumn 35, Issue 10, 2009, Pages 858-882

  Kirby, Patrick J ^a   Shines, Cassandra J ^a   Taylor, Genie J ^b   Bousquet, Ronald W ^b   Price, Herman C ^b   Everitt, Jeffrey I ^c   Morgan, Daniel L ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b ALION SCIENCE AND TECHNOLOGY   (United States)

^c Pathology Consultant   (United States)

Author keywords

Indium phosphide; Lung; Mice; Particulate; Pleural fibrosis

Indexed keywords

INDIUM; LACTATE DEHYDROGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPIRATION; CELL COUNT; DISEASE COURSE; LUNG LAVAGE; MALE; MOUSE; NONHUMAN; PLEURA EFFUSION; PLEURA FLUID; PLEURA THICKENING; PLEURAL FIBROSIS; PRIORITY JOURNAL;

ADMINISTRATION, INHALATION; ANIMALS; BRONCHOALVEOLAR LAVAGE FLUID; CYTOKINES; DISEASE MODELS, ANIMAL; FIBROSIS; INDIUM; INHALATION EXPOSURE; L-LACTATE DEHYDROGENASE; MALE; MICE; PARTICULATE MATTER; PHOSPHINES; PLEURA; PLEURAL EFFUSION; PLEURISY; TIME FACTORS;

EID: 72049125617     PISSN: 01902148     EISSN: 15210499     Source Type: Journal    
DOI: 10.3109/01902140902980961     Document Type: Article

References (41)

1. ACGIH: Threshold Limit Values for Chemical Substances and Physical Agents, and Biological Exposure Indices. Cincinnati, OH: American Conference of Governmental Industrial Hygienists; 2007;35.
2. Kabe I, et al: In vitro solubility and in vivo toxicity of indium phosphide. J Occup Health. 1996;38:6-12.
3. Oda K: Toxicity of a low level of indium phosphide (InP) in rats after intratracheal instillation. Ind Health. 1997;35(1):61-68.
4. Uemura T, et al: Effects of intratracheally administered indium phosphide on male Fischer 344 rats. J Occup Health. 1997;39:205-210.
5. Omura M, et al: Testicular toxicity of gallium arsenide, indium arsenide, and arsenic oxide in rats by repetitive intratracheal instillation. Fundam Appl Toxicol. 1996;32:72-78.
6. Tanaka A, et al: Chronic toxicity of indium arsenide and indium phosphide to the lungs of hamsters. Fukuoka Igaku Zasshi. 1996;87:108-115.
7. Tanaka A, et al: Comparative study of the toxic effects of gallium arsenide, indium arsenide and arsenic trioxide following intratracheal instillations to the lung of Syrian golden hamsters. Fukuoka Igaku Zasshi. 2000;91:21-33.
8. Morgan DL, et al: Acute pulmonary toxicity of copper gallium diselenide, copper indium diselenide, and cadmium telluride intratracheally instilled into rats. Environ Res. 1995;71:16-24.
9. Tanaka A, et al: Pulmonary toxicity of indium-tin oxide and indium phosphide after intratracheal instillations into the lung of hamsters. J Occup Health. 2002;44:99-102.
10. Chonan T, Taguchi O, Omae K: Interstitial pulmonary disorders in indium-processing workers. Eur Respir J. 2007;29:317-324.
11. Homma T, et al: Interstitial pneumonia developed in a worker dealing with particles containing indium-tin oxide. J Occup Health. 2003;45:137-139.
12. Homma S, et al: Pulmonary fibrosis in an individual occupationally exposed to inhaled indium-tin oxide. Eur Respir J. 2005;25:200-204.
13. Hamaguchi T, et al: Exposure to hardly soluble indium compounds in ITO production and recycling plants is a new risk for interstitial lung damage. Occup Environ Med. 2008;65:51-55.
14. Taguchi O, Chonan T: Three cases of indium lung. Nihon Kokyuki Gakkai Zasshi. 2006;44:532-536.
15. NTP, Toxicology and carcinogenesis studies of indium phosphide (CAS no. 22398-90-7) in F344/N rats and B6C3F1 mice (inhalation studies). National Toxicology Program Techical Report Series; 2001;7-340.
16. McNulty JC: Malignant pleural mesothelioma in an asbestos worker. Med J Aust. 1962;49:953-954.
17. Wagner JC, Sleggs CA, Marchand P: Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med. 1960;17:260-271.
18. Hesterberg TW, et al: Studies on the inhalation toxicology of two fiberglasses and amosite asbestos in the syrian golden hamster. Part I. Results of a subchronic study and dose selection for a chronic study. Inhal Toxicol. 1999;11:747-784.
19. Foster WM, et al: Methodology for the measurement of mucociliary function in the mouse by scintigraphy. J Appl Physiol. 2001;90:1111-1117.
20. Card JW, et al: Gender differences in murine airway responsiveness and lipopolysaccharide-induced inflammation. J Immunol. 2006;177:621-630.
21. Card JW, et al: Cyclooxygenase-2 deficiency exacerbates bleomycin-induced lung dysfunction but not fibrosis. Am J Respir Cell Mol Biol. 2007;37:300-308.
22. Kirby PK, et al: Pleural effects of indium phosphide in B6C3F1mice: nonfibrous particulate induced pleural fibrosis. Exp. Lung Res. 2009, in press.
23. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
24. Noppen M: Normal volume and cellular contents of pleural fluid. Curr Opin Pulm Med. 2001;7:180-182.
25. NoppenM:Normal volume and cellular contents of pleural fluid. Paediatr Respir Rev. 2004;5(Suppl A):S201-S203.
26. Henderson RF: Bronchoalveolar lavage: a tool for assessing the health status of the lung. In: McClellam RO, Henderson RF, eds. Concepts in Inhalation Toxicology. New York: Hemisphere; 1989;415-444.
27. Stephens M, et alet al: Asbestos induced diffuse pleural fibrosis: pathology and mineralogy. Thorax. 1987;42:583-588.
28. Huggins JT, Sahn SA: Causes and management of pleural fibrosis. Respirology. 2004;9:441-447.
29. Jantz MA, Antony VB: Pleural fibrosis. Clin Chest Med. 2006;27:181-191.
30. Mutsaers SE, et al: Growth factors in pleural fibrosis. Curr Opin Pulm Med. 2006;12:251-258.
31. Mutsaers SE, et al: Pathogenesis of pleural fibrosis. Respirology. 2004;9:428-440.
32. Jantz MA, Antony VB: Pathophysiology of the pleura. Respiration. 2008;75:121-133.
33. Gomez DE, et al: Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol. 1997;74:111-122.
34. Iglesias D, et al: Metalloproteinases and tissue inhibitors of metalloproteinases in exudative pleural effusions. Eur Respir J. 2005;25:104-109.
35. Decologne N, et al: TGF-beta1 induces progressive pleural scarring and subpleural fibrosis. J Immunol. 2007;179:6043-6051.
36. Davis JM, Jones AD: Comparisons of the pathogenicity of long and short fibres of chrysotile asbestos in rats. Br J Exp Pathol. 1988;69:717-737.
37. Dittmar TB, et al: Surface concentrations of indium, phosphorus, and oxygen in indium phosphide single crystals after exposure to Gamble solution. Anal Chem. 1992;64:2929-2933.
38. Galle P, Berry JP,Galle C: Role of alveolarmacrophages in precipitation of mineral elements inhaled as soluble aerosols. Environ Health Perspect. 1992;97:145-147.
39. Gjomarkaj M, et al: Phenotypic and functional characterization of normal rat pleural macrophages in comparison with autologous peritoneal and alveolar macrophages. Am J Respir Cell Mol Biol. 1999;20:135-142.
40. Antony VB: Immunological mechanisms in pleural disease. Eur Respir J. 2003;21:539-544.
41. Quintana HK, et al: Identification with MRI of the pleura as a major site of the acute inflammatory effects induced by ovalbumin and endotoxin challenge in the airways of the rat. Am J Physiol Lung Cell Mol Physiol. 2006;291:L651-L657.